Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tesaglitazar 是一种有效且具有选择性的过氧化物 PPAR α / γ受体双重激动剂,对 PPARγ的亲和力比 PPARα更有效,对大鼠PPARα和人PPARα的EC50分别为13.4 μM 和3.6 μM,对大鼠PPARγ和人类 PPARγ的EC50都是0.2 μM。Tesaglitazar 诱导大鼠皮下组织间质间充质细胞DNA 合成和纤维肉瘤形成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 395 | 现货 | ||
5 mg | ¥ 747 | 现货 | ||
10 mg | ¥ 1,120 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,530 | 现货 | ||
100 mg | ¥ 4,950 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 869 | 现货 |
产品描述 | Tesaglitazar is a potent and selective peroxide PPARα / γ receptor dual agonist with a more potent affinity for PPARγ than PPARα, The EC50 values for rat PPARα and human PPARα were 13.4 μM and 3.6 μM, respectively, and 0.2 μM for rat PPARγ and human PPARγ. Tesaglitazar induced DNA synthesis and fibrosarcoma formation in rat subcutaneous mesenchymal cells. |
靶点活性 | PPARα(human):3.6 μM(EC50), PPARγ:0.2 μM(EC50), PPARα (rat):13.4 μM(EC50) |
体内活性 | The aim of the present study was to determine whether tesaglitazar attenuates NAFLD and atherosclerosis development in diabetic low-density lipoprotein receptor-deficient (LDLr(-/-)) mice. Tesaglitazar therapeutic group (n=15, 20 μg/kg/day oral treatment for 6 weeks). Tesaglitazar decreased serum glucose and lipid levels compared with the diabetic mice and significantly reduced atherosclerotic lesions, lipid accumulation in the liver, macrophage infiltration, and decreased total hepatic cholesterol and triglyceride content compared to the diabetic mice. In addition, tesaglitazar reduced inflammatory markers at both the serum and mRNA levels. Tesaglitazar may be effective in preventing NAFLD and atherosclerosis in a pre-existing diabetic condition by regulating glucose and lipid metabolism, and the inflammatory response.[1] |
分子量 | 408.47 |
分子式 | C20H24O7S |
CAS No. | 251565-85-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 180.0 mg/mL (440.7 mM), Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4482 mL | 12.2408 mL | 24.4816 mL | 61.204 mL |
5 mM | 0.4896 mL | 2.4482 mL | 4.8963 mL | 12.2408 mL | |
10 mM | 0.2448 mL | 1.2241 mL | 2.4482 mL | 6.1204 mL | |
20 mM | 0.1224 mL | 0.612 mL | 1.2241 mL | 3.0602 mL | |
50 mM | 0.049 mL | 0.2448 mL | 0.4896 mL | 1.2241 mL | |
100 mM | 0.0245 mL | 0.1224 mL | 0.2448 mL | 0.612 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tesaglitazar 251565-85-2 DNA Damage/DNA Repair Metabolism PPAR Inhibitor inhibitor inhibit